A Phase 1/2, multi-center, Open-label, Dose-finding Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986458, alone and in combination with antilymphoma agents in Subjects with Relapsed/Refractory non-Hodgkin lymphomas (R/R NHL)

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506654-20-00

Acronym

CA123-1000

Enrollment

231

Registered

2024-02-20

Start date

2024-03-11

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin Lymphomas

Brief summary

Incidence of adverse events (AEs), Serious adverse events (SAEs), AEs meeting protocol defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, and death

Detailed description

Summary measures of BMS-986458 PK parameters, Overall response rate, Duration of response, Time to response, Progression free survival, Overall Survival

Interventions

DRUGB-cell Lymphoma 6 Ligand Directed Degrader (BCL6-LDD)

DRUGRITUXIMAB

DRUGOBINUTUZUMAB

DRUGGLOFITAMAB

DRUGMOSUNETUZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events (AEs), Serious adverse events (SAEs), AEs meeting protocol defined dose limiting toxicity (DLT) criteria, AEs leading to discontinuation, and death	—

Secondary

Measure	Time frame
Summary measures of BMS-986458 PK parameters, Overall response rate, Duration of response, Time to response, Progression free survival, Overall Survival	—

Countries

France, Germany, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026